ConsumerLab.com has voluntarily dismissed a lawsuit that it brought against the Council for Responsible Nutrition in 2005, which made claims such as injurious falsehoods, trade libel and unfair trade practices, CRN announces Nov. 17. ConsumerLab filed the suit after FTC declined a January 2005 request by CRN to investigate the business practices of the company, which tests supplements for potency and contaminants. In May, a New York Supreme Court judge dismissed eight of ConsumerLab's nine counts, allowing the case to proceed only on the charge of defamation (1"The Tan Sheet" May 29, 2006, p. 9). According to CRN, ConsumerLab dropped the lawsuit "as CRN was about to ask the Court to require ConsumerLab.com to produce additional information and documents about its business practices." In a same-day release, ConsumerLab responded that it dropped the suit because "CRN's legal tactics forced [us] to divert an extraordinary amount of resources to the case"...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.
Pink Sheet reporter and editors consider the issues that could emerge during upcoming private FDA forums with pharma CEOs, as well as the impact of the surprising move by HHS Secretary Robert F. Kennedy Jr. to limit the CDC recommendation for annual COVID-19 vaccine boosters.
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
